Advancing Precision Medicine in Neuropsychiatry with Personalized Synapse Proteomics

Neuropsychiatric disorders such as Alzheimer's disease, depression, schizophrenia, and bipolar disorder are significant public health challenges, leading to long-lasting disabilities for millions of individuals. Despite decades of research, there is still no cure for these brain diseases, and clinical trials often fail, with Alzheimer's drugs having a staggering 99.6% failure rate. A significant reason for this is the complexity and variability of the molecular causes underlying these conditions, which differ significantly among patients, even when their symptoms appear similar.

To address these challenges, a team led by neuroscientist Dr. Zacharie Taoufiq at OIST has developed an innovative approach: personalized synapse proteomics (PSP). This strategy focuses on synapses—the communication hubs between neurons that play a crucial role in brain function and are often disrupted in mental disorders. Dr. Taoufiq's team has pioneered a non-invasive method to study synapses in living patients by combining stem cell programming with advanced proteomics. By recreating neurons from a patient's blood sample and analyzing their synaptic protein composition, this cutting-edge technology offers a detailed view of the brain's molecular landscape.

The PSP technology provides unprecedented levels of molecular data, which are expected to enable the recognition, stratification, and ultimately the deciphering of patient psychiatric conditions with exceptional precision. This approach has already shown promising results, successfully differentiating between schizophrenia patients and healthy individuals through AI-based analysis. Ultimately, this research could revolutionize the diagnosis and treatment of neuropsychiatric disorders, paving the way for more effective and personalized therapies.

This groundbreaking project has been supported by OIST's Proof of Concept Program, enabling the team to validate their technology. They are now actively seeking collaborations with hospitals and the pharmaceutical industry to further advance this transformative solution and revolutionize neuropsychiatric care.

To learn more about this transformative technology, watch the following video:​